The “BI Biostatistics Scholarship” Was Founded at NMU

Boehringer Ingelheim (BI), which is the world’s largest private pharmaceutical group, has established ties with Nanjing Medical University (NMU) and on December 6th 2013signed a contract to establish a “BI Biostatistics Scholarship” at NMU. The signing ceremony was attended by Mr. Xiaoxiang Chen - Vice President of Medicine Department of BI, Dr. Wei Zhang and Dr. Luyan Dai - Executive Director and Deputy Director of Biological Statistics and Data Management at BI, Ms. Yiyi Zhan and Mr. Xiangdao Wang from the Human Resources Department of BI, as well as other head and teacher representatives of the NMU School of Public Health (SPH).
At the ceremony, the Dean of SPH, Dr. Feng Chen, introduced the latest developments at SPH and explained the Biostatistics major. Vice-President Xiaoxiang Chen then introduced BI and made a donation to the school. Dr. Feng Chen issued a donation certificate to BI on behalf of the NMU Education Development Foundation. Following, BI gave a speech to the teachers and students about their company and about the scholarship.
The “BI Biostatistics Scholarship” was founded to encourage student research groups in biostatistics, to stimulate interest in young college students engaged in biostatistical work, to give opportunities to work in teams and to improve students’ conscientiousness. Student research teams participating in the competition should consist of 3-6 graduates and/or undergraduates must select research topics according to the research directions in biostatistics advised by BI, propose research hypotheses and design a research timeline and an outline of the necessary preparations. The research plan will be assessed jointly by experts from NMU SPH and by BI. A total of 30,000 RMB will be available for the winning team. The first phase of the “BI Biostatistics Scholarship” at NMU will be five years, according to the contract.
BI is currently the world’s largest private pharmaceutical group. Since its establishment in 1885, the company has been committed to the development, production and marketing of innovative drugs. After one hundred years of development, BI's footprint extends from the Rhine in Germany to more than 40 countries and regions worldwide, and has successfully become one of the world's top 20 pharmaceutical companies. BI International Trading (Shanghai) Co., Ltd. was founded in May 1995. To date, BI’s main products in China include prescription drugs and medicines for human and animal health care, covering important medical areas such as respiratory, cardiovascular and central nervous system health, as well as anti-AIDS drugs.
Reported by: The School of Public Health
Edited by: Anthony Williams